An observational study of nearly 35,000 Scandinavian patients with type 2 diabetes (T2D) has found sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of prescription drugs approved by the FDA to lower blood sugar in adults with T2D, may almost double patients’ risks of lower limb amputation and diabetic ketoacidosis compared to glucagon-like peptide 1 (GLP1) receptor agonists.
Thumbnail
The shortage of Molybdenum-99 (Mo-99), which is used to create the crucial nuclear imaging…
Thumbnail
Heart patients with symptoms of peripheral artery disease (PAD) continue to see low rates of…
Thumbnail
A machine learning-based risk calculator developed to assess an individual’s long-term risk for…
Thumbnail
A new study published in Circulation emphasized the importance of prompt arterial switch operations…
Thumbnail
Violence, an ever-growing presence in our global communities, isn’t just a social issue, according…
Thumbnail
The FDA plans to take aggressive steps toward limiting youth access to tobacco products and banning…